Prevalence of Megaloblastic Anemia in Type 2 Diabetes Patients Taking Long-term Metformin with Vitamin B Supplements
Keywords:
megaloblastic anemia, metformin, vitamin B, type 2 diabetes mellitusAbstract
Long-term use of metformin is associated with vitamin B12 deficiency, which can lead to megaloblastic anemia. Vitamin B supplementation is often provided to patients receiving metformin. This cross-sectional descriptive study aims to investigate the prevalence of megaloblastic anemia in patients with type 2 diabetes
receiving long-term metformin with vitamin B supplementation. The data were collected from the Outpatients Department at King Chulalongkorn Memorial Hospital, Thai Red Cross Society, from January 1st, 2023, to
December 31st, 2024.
Out of a total of 161 patients, 113 (70.2%) were female. The median age is 74 years (interquartile range 65-81 years). Dose per day of metformin ranged from 1,000 to 3,000 milligrams. The most common comorbidities were hypertension and hyperlipidemia (126 patients; 78.26%). The most prescribed oral vitamin B products were vitamin B complex (79 patients; 63.49%) which contain vitamin B 12 20-200 micrograms per tablet. The prevalence of megaloblastic anemia in this study was 2.5% (4 out of 161 patients). However, no
correlation was found between the dose of metformin and the dose of vitamin B12 in vitamin B supplement products with the occurrence of megaloblastic anemia in this group of participants (p-value = 0.824 and
p-value = 0.358, respectively).
Megaloblastic anemia is still found in patients with type 2 diabetes who have received long-term metformin with vitamin B supplementation. However, due to the small sample size and the unknown adherence to the medications among the patients, further studies are needed
References
World Health Organization. Diabetes [internet]. 2023 [cited 2024 Feb 25]. Available from: https://www.who.int/newsroom/factsheets/detail/diabetes#:~:text=Overview,hormone%20that%20regulates%20blood%20glucose.
International Diabetes Federation. IDF Diabetes Atlas: Thailand diabetes report 2000–2045 [Internet]. 2021 [cited 2024 Feb 25]. Available from: https://diabetesatlas.org/data/en/country/196/th.html
Centers for Disease Control and Prevention. Prevent diabetes complications [internet]. 2022 [cited 2024 Feb 25]. Available from: https://www.cdc.gov/diabetes/managing/problems.html
สถาบันโรคเบาหวานแห่งประเทศไทย ในพระราชูปถัมภ์สมเด็จพระเทพรัตนราชสุดาฯ สยามบรมราชกุมารี. แนวทางเวชปฏิบัติสำหรับโรคเบาหวาน 2566 [อินเตอร์เน็ต]. 2566 [เข้าถึงเมื่อวันที่ 25 กุมภาพันธ์ 2567]. เข้าถึงได้จาก: https://drive.google.com/file/d/1OAIDiCyGsJYA1-wTAxoOu6yL_YL9c7IG/view
Makin V. Lansang M.C. Should metformin be used in every patient with type 2 diabetes? Cleve Clin J Med. 2019;86:17–9.
Kim J, Ahn CW, Fang S, Lee HS, Park JS. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019;98(46):e17918.
Porter KM, Ward M, Hughes CF, O'Kane M, Hoey L, McCann A, et al. Hyperglycemia and metformin use are associated with B vitamin deficiency and cognitive dysfunction in older adults. J Clin Endocrinol Metab. 2019;104(10):4837-47.
สมาคมโลหิตวิทยาแห่งประเทศไทย. Megaloblastic Anemia. แนวทางเวชปฏิบัติสำหรับการรักษาโลหิตจางและธาลัสซีเมีย 2019;5:47-60.
Densupsoontorn N, Sumboonnanonda R. Vitamin B12 and clinical application. Thai JPEN 2020;28(2):66-77.
Filioussi K, Bonovas S, Katsaros T. Should we screen diabetic patients using biguanides for megaloblastic anaemia? Aust Fam Physician. 2003;32(5):383-4.
Rehman HU. Vitamin B12 deficiency: some observations, some misconceptions. Eur J Gen Med. 2015;12(3):261-6.
Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149-160.
Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med. 2006;166(18):1975-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Thai JPEN วารสารโภชนบำบัด

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The content and information in the articles published in Thai JPEN วารสารโภชนบำบัด, are the opinions and responsibility of the authors directly. The editorial team is not obliged to agree or take any responsibility.
All articles, content, figures, etc. that have been published in Thai JPEN วารสารโภชนบำบัด are the copyright of Thai JPEN วารสารโภชนบำบัด. If any person or organization require distribution of all or any part of them, please send the request for the written permission from Thai JPEN วารสารโภชนบำบัด only.